Certain disease and transplant-related factors—along with patient socioeconomic status—can predict long-term survival after allogeneic hematopoietic cell transplantation (allo-HCT), researchers concluded after conducting a study involving 413 individuals. Participants underwent first-time allo-HCT between 2006 and 2014. Three-fourths received a myeloablative transplant; bone marrow was used in ~half. Investigators looked at predictors of surviving >100 days. Among the results:

• 1-year all-cause mortality rate was 29%.
• Relapse mortality and non-relapse mortality rates were 16% and 12%, respectively.
• Patients who relapsed within the first 100 days had a >4-fold elevated risk of worse all-cause mortality.
• Those with high-risk disease and non-cytomegalovirus infection had elevated all-cause mortality risk of 55% and 79%, respectively.
• Patients who received bone marrow and umbilical cord blood had 48% and 60% lower risk of all-cause mortality, respectively.
• Longer hospitalization increased the risk by 16%, whereas higher income lowered it by 11%.